Pharmaceuticals company AstraZeneca Pharma India announced Q1FY25 results: Revenue from Operation for the quarter stood at Rs 3,875.2 million with substantial 31% increase demonstrating Company’s focus on improving access to patients. Profit before exceptional item and tax is Rs 424 million (11% of the total Income ) reflecting the Company’s efforts on driving profitable growth. Loss after exceptional item and tax is Rs 117.9 million ( -3% of total income ) due to booking of provisions associated with exit of factory site announced in this quarter. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations." Bhavana Agrawal, Chief Finance Officer, added, "It’s a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of Company’s focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.” Result PDF